Company intelligence / Profile preview

Hongji Bio

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Hongji Bio is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of innovative gene therapies. The company focuses on utilizing adeno-associated virus (AAV) vectors to treat chronic and rare diseases, with a primary emphasis on ophthalmology. Its lead program, HJ001, is an AAV-based gene therapy designed for the treatment of neovascular age-related macular degeneration (nAMD). Hongji Bio aims to provide long-term therapeutic benefits through a single administration, reducing the burden of frequent intravitreal injections for patients. The company is supported by prominent venture capital firms and maintains a robust R&D infrastructure for vector design and process development.

Therapeutic areas: Ophthalmology
Modalities: Gene therapyAAV vector
Industry: Biotech

Beyond the preview

Go deeper on Hongji Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hongji Bio.

Explore the full profile